Haloperidol Richter

Haloperidol Richter is an intramuscular injection that contains the butyrophenone antipsychotic haloperidol as its active ingredient. Marketed in the European Union, the product’s exact strength is not disclosed on the label. Classified as a Schedule IV controlled substance, Haloperidol Richter is used under medical supervision for conditions that require rapid antipsychotic intervention and may be administered by a qualified healthcare professional in acute care settings in hospitals.

Haloperidol Richter is indicated for the short‑term management of several acute psychiatric conditions where rapid control of symptoms is required.

- Acute exacerbations of schizophrenia requiring intramuscular antipsychotic therapy. - Sudden onset of psychotic symptoms in patients with schizophrenia or related disorders. - Manic episodes of bipolar disorder presenting with severe agitation or psychosis. - Severe agitation or aggression in patients who are unable to take oral medication. - Pre‑operative or emergency sedation when rapid tranquilization is clinically indicated. - Acute delirium with psychotic features in medically unstable patients.

Haloperidol Richter, like other haloperidol preparations, may cause neurologic and systemic effects that differ in frequency and severity overall.

Common: - Extrapyramidal symptoms such as dystonia, akathisia, or parkinsonian rigidity may appear, especially after the first few injections. - Sedation or drowsiness can occur, potentially affecting alertness and the ability to perform tasks that require concentration. - Dry mouth, blurred vision, or mild gastrointestinal upset like constipation are frequently reported. - Gastrointestinal disturbances, including nausea or reduced bowel motility, may be experienced during treatment.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening reaction characterized by high fever, muscle rigidity, and autonomic instability, requires immediate medical attention. - Tardive dyskinesia, presenting as persistent involuntary facial or limb movements, may develop after prolonged exposure. - Severe hypotension, cardiac arrhythmias, or seizures can occur, particularly in patients with underlying cardiovascular disease. - Elevated prolactin levels may lead to galactorrhea, gynecomastia, or menstrual irregularities, necessitating endocrine evaluation.

When prescribing Haloperidol Richter, clinicians should evaluate patient history and monitor for specific safety concerns.

- Assess cardiovascular history, including arrhythmias or uncontrolled hypertension, before administration. - Evaluate prior extrapyramidal reactions or known hypersensitivity to haloperidol. - Use caution in hepatic or renal impairment; adjust monitoring accordingly. - Monitor for neuroleptic malignant syndrome during the initial treatment phase. - Consider pregnancy, lactation, and QT‑prolonging drug interactions; weigh risks versus benefits. - Review concurrent medications that may affect dopamine pathways.

Haloperidol Richter can interact with several medicines, altering its effectiveness or increasing the risk of adverse events.

Avoid: - Other central nervous system depressants such as benzodiazepines in high doses (risk of excessive sedation). - Medications that strongly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics). - Monoamine oxidase inhibitors (MAOIs) within 14 days of haloperidol administration.

Use with caution: - Antipsychotics or dopamine antagonists (may increase extrapyramidal effects). - Anticholinergic agents (can mask early signs of extrapyramidal symptoms). - CYP3A4 inhibitors or inducers (affect haloperidol plasma levels). - Lithium (combined use may increase neurotoxicity).